熱門資訊> 正文
Vertex为Alyfrek囊性纤维化治疗获得NHS英格兰报销协议
2025-07-15 14:18
- Vertex Pharmaceuticals (NASDAQ:VRTX) has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicine, Alyftrek.
- This agreement comes as the National Institute for Health and Care Excellence has issued a positive final draft recommendation for this medicine.
- This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
- Following the European regulatory approval, eligible patients in Ireland, Denmark, and Germany will be the first ones to access deutivacaftor/tezacaftor/vanzacaftor in the European Union.
- Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible.
More on Vertex Pharmaceuticals
- Why Vertex Pharmaceuticals Continues To Outperfrom
- Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
- ADA IR Presentation_v FINAL PDF
- Vertex unveils longer-term data on Casgevy
- Vertex gets EU nod for Alyftrek
推薦文章
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
